Health & BioTech
Alimera Sciences Shares Plunge 20% Amid Lawsuit Against ANI Pharmaceuticals Merger
Alimera Sciences Shares Drop After Merger Lawsuit Alimera Sciences saw its shares drop significantly on Tuesday. The company announced a lawsuit against ANI Pharmaceuticals, aiming...
Butterfly Network Soars as Fierce 50 Honoree Amidst Stock Surge
Butterfly Network Makes Waves in Healthcare Innovation Butterfly Network, Inc (NYSE: BFLY), a leader in portable ultrasound technology, has achieved a significant milestone. The company...
Tango Therapeutics Stock Slides Despite Strong Analyst Ratings and Positive Earnings
Market Slump for Tango Therapeutics Stock The stock of Tango Therapeutics (NASDAQ: TNGX) experienced a significant decline before the market opened on Monday. Tango Therapeutics...
TC BioPharm Announces Preclinical Studies for Monkeypox Treatment
TC BioPharm Announces Preclinical Studies for TCB008 TC BioPharm, a biotechnology company specializing in gamma-delta T cell therapies, has announced its plans to initiate preclinical...
Oragenics Faces Decline as Stock Offering Hits Market
Oragenics Announces Stock Offering Oragenics, Inc (NYSE American: OGEN) has announced a new stock offering. The company will issue 8,106,584 shares of common stock at...
Recursion Pharmaceuticals Plunges 15% After Mixed Phase 2 Trial Results for CCM Treatment
Recursion Pharmaceuticals Faces Market Backlash After Phase 2 Trial Results Update Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell sharply on Tuesday, after the company released...
IO Biotech: Clinical Trials Progress: Analysts Adjust Ratings Amid New Data
Jefferies Lowers Price Target for IO Biotech Jefferies has maintained its “Buy” rating for IO Biotech (NASDAQ: IOBT) but has reduced its price target from...
Dyne Therapeutics Strengthens Leadership Team Amid Strategic Shift to Drive Growth
Dyne Therapeutics Announces Key Leadership Changes Dyne Therapeutics (Nasdaq: DYN), a clinical-stage company specializing in muscle disease therapeutics, has unveiled significant leadership appointments to bolster...
NuCana Shares Plunge 50% After Second Clinical Trial Setback in Two Years
NuCana Stock Hit Hard by Phase II Clinical Trial Failure NuCana shares plunged by half on Friday morning following the Phase II failure of a...
Coscien Biopharma Stock Plunges After Late-Stage Trial Failure
Coscien Biopharma Stock Plummets After Trial Setback The stock of Coscien Biopharma nosedived following disappointing news from its late-stage clinical trial. The company revealed that...
